메뉴 건너뛰기




Volumn 59, Issue 9, 2015, Pages 5503-5510

Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; DACLATASVIR; METHADONE; OPIATE; BMS-790052; BUPRENORPHINE; IMIDAZOLE DERIVATIVE; NORBUPRENORPHINE;

EID: 84940902228     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00478-15     Document Type: Article
Times cited : (23)

References (41)
  • 7
    • 80051676859 scopus 로고    scopus 로고
    • Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews
    • Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. 2011. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378: 571-583. http://dx.doi.org/10.1016/S0140-6736(11)61097-0.
    • (2011) Lancet , vol.378 , pp. 571-583
    • Nelson, P.K.1    Mathers, B.M.2    Cowie, B.3    Hagan, H.4    Des Jarlais, D.5    Horyniak, D.6    Degenhardt, L.7
  • 8
    • 84929924393 scopus 로고    scopus 로고
    • Prevalence of HIV, hepatitis C and depression among people who inject drugs in the Kinondoni municipality in Dar es Salaam, Tanzania, abstr 473/poster 113
    • San Diego, CA, 15 to 20 June
    • Nyandindi C, Mbwambo J, McCurdy S, Lambdin B, Copenhaver M, Bruce R. 2013. Prevalence of HIV, hepatitis C and depression among people who inject drugs in the Kinondoni municipality in Dar Es Salaam, Tanzania, abstr 473/poster 113. 75th Annu Meet College Problems Drug Dependence, San Diego, CA, 15 to 20 June 2013.
    • (2013) 75th Annu Meet College Problems Drug Dependence , vol.2013
    • Nyandindi, C.1    Mbwambo, J.2    McCurdy, S.3    Lambdin, B.4    Copenhaver, M.5    Bruce, R.6
  • 9
    • 77649275644 scopus 로고    scopus 로고
    • Methadone as HIV prevention: High volume methadone sites to decrease HIV incidence rates in resource limited settings
    • Bruce RD. 2010. Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int J Drug Policy 21:122-124. http://dx.doi.org/10.1016/j.drugpo.2009.10.004.
    • (2010) Int J Drug Policy , vol.21 , pp. 122-124
    • Bruce, R.D.1
  • 10
    • 84940940324 scopus 로고    scopus 로고
    • Gendelman HE, Grant I, Everall IP, Fox HS, Gelband HA, Lipton SA, Swindells S (Ed), Neurology of AIDS, 3rd Ed. Oxford University Press, New York, NY
    • Bruce RD. 2011. Medical interventions for addiction, p 581-600. In Gendelman HE, Grant I, Everall IP, Fox HS, Gelband HA, Lipton SA, Swindells S (ed), Neurology of AIDS, 3rd ed. Oxford University Press, New York, NY.
    • (2011) Medical Interventions for Addiction , pp. 581-600
    • Bruce, R.D.1
  • 11
    • 84887015331 scopus 로고    scopus 로고
    • Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior-outcomes of a randomized trial
    • Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE. 2013. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior-outcomes of a randomized trial. Drug Alcohol Depend 133:376-382. http://dx.doi.org/10.1016/j.drugalcdep.2013.06.024.
    • (2013) Drug Alcohol Depend , vol.133 , pp. 376-382
    • Otiashvili, D.1    Piralishvili, G.2    Sikharulidze, Z.3    Kamkamidze, G.4    Poole, S.5    Woody, G.E.6
  • 12
    • 78651012481 scopus 로고
    • Pharmacologic comparison of the optical isomers of methadon
    • Scott CC, Robbins EB, Chen KK. 1948. Pharmacologic comparison of the optical isomers of methadon. J Pharmacol Exp Ther 93:282-286.
    • (1948) J Pharmacol Exp Ther , vol.93 , pp. 282-286
    • Scott, C.C.1    Robbins, E.B.2    Chen, K.K.3
  • 13
    • 0014867155 scopus 로고
    • Localization of d- and l-methadone after intraventricular injection into rat brains
    • Ingoglia NA, Dole VP. 1970. Localization of d- and l-methadone after intraventricular injection into rat brains. J Pharmacol Exp Ther 175: 84-87.
    • (1970) J Pharmacol Exp Ther , vol.175 , pp. 84-87
    • Ingoglia, N.A.1    Dole, V.P.2
  • 14
    • 0038193696 scopus 로고    scopus 로고
    • Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro
    • Wang JS, DeVane CL. 2003. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 31:742-747. http://dx.doi.org/10.1124/dmd.31.6.742.
    • (2003) Drug Metab Dispos , vol.31 , pp. 742-747
    • Wang, J.S.1    DeVane, C.L.2
  • 15
    • 0347383736 scopus 로고    scopus 로고
    • Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19
    • Gerber JG, Rhodes RJ, Gal J. 2004. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16: 36-44. http://dx.doi.org/10.1002/chir.10303.
    • (2004) Chirality , vol.16 , pp. 36-44
    • Gerber, J.G.1    Rhodes, R.J.2    Gal, J.3
  • 16
    • 33947412998 scopus 로고    scopus 로고
    • Enantiomeric metabolic interactions and stereoselective human methadone metabolism
    • Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. 2007. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 321:389-399. http://dx.doi.org/10.1124/jpet.106.117580.
    • (2007) J Pharmacol Exp Ther , vol.321 , pp. 389-399
    • Totah, R.A.1    Allen, K.E.2    Sheffels, P.3    Whittington, D.4    Kharasch, E.D.5
  • 18
    • 17844409048 scopus 로고    scopus 로고
    • In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways
    • Picard N, Cresteil T, Djebli N, Marquet P. 2005. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos 33:689-695. http://dx.doi.org/10.1124/dmd.105.003681.
    • (2005) Drug Metab Dispos , vol.33 , pp. 689-695
    • Picard, N.1    Cresteil, T.2    Djebli, N.3    Marquet, P.4
  • 19
    • 69949093628 scopus 로고    scopus 로고
    • Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP glucuronosyltransferases
    • Chang Y, Moody DE. 2009. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP glucuronosyltransferases. Drug Metab Lett 3:101-107. http://dx.doi.org/10.2174/187231209788654117.
    • (2009) Drug Metab Lett , vol.3 , pp. 101-107
    • Chang, Y.1    Moody, D.E.2
  • 20
    • 73149100796 scopus 로고    scopus 로고
    • Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes
    • Rouguieg K, Picard N, Sauvage FL, Gaulier JM, Marquet P. 2010. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos 38:40-45. http://dx.doi.org/10.1124/dmd.109.029546.
    • (2010) Drug Metab Dispos , vol.38 , pp. 40-45
    • Rouguieg, K.1    Picard, N.2    Sauvage, F.L.3    Gaulier, J.M.4    Marquet, P.5
  • 24
    • 84892728051 scopus 로고    scopus 로고
    • Daclatasvir, an HCV NS5A replication complex inhibitor, has minimal effect on pharmacokinetics of midazolam, a sensitive probe for cytochrome P450 3A4, abstr O-15
    • Cambridge, MA, 26 to 27 June 2013. (Presentation)
    • Bifano M, Sevinsky H, Stonier M, Jiang H, Bertz RJ. 2013. Daclatasvir, an HCV NS5A replication complex inhibitor, has minimal effect on pharmacokinetics of midazolam, a sensitive probe for cytochrome P450 3A4, abstr O-15. 8th Int Workshop Clin Pharmacol Hepatitis Ther, Cambridge, MA, 26 to 27 June 2013. (Presentation available at http://regist2.virology-education.com/2013/8hepcam/docs/21-Bertz.pdf.)
    • (2013) 8th Int Workshop Clin Pharmacol Hepatitis Ther
    • Bifano, M.1    Sevinsky, H.2    Stonier, M.3    Jiang, H.4    Bertz, R.J.5
  • 25
    • 0041665111 scopus 로고    scopus 로고
    • The clinical opiate withdrawal scale (COWS)
    • Wesson DR, Ling W. 2003. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 35:253-259. http://dx.doi.org/10.1080/02791072.2003.10400007.
    • (2003) J Psychoactive Drugs , vol.35 , pp. 253-259
    • Wesson, D.R.1    Ling, W.2
  • 27
    • 27144449749 scopus 로고    scopus 로고
    • Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction
    • Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E. 2005. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 19:1635-1641. http://dx.doi.org/10.1097/01.aids.0000183628.20041.f2.
    • (2005) AIDS , vol.19 , pp. 1635-1641
    • Friedland, G.1    Andrews, L.2    Schreibman, T.3    Agarwala, S.4    Daley, L.5    Child, M.6    Shi, J.7    Wang, Y.8    O'Mara, E.9
  • 28
    • 84861963822 scopus 로고    scopus 로고
    • A sensitive and accurate liquid chromatography- tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclatasvir) in human plasma and urine
    • Jiang H, Zeng J, Kandoussi H, Liu Y, Wang X, Bifano M, Cojocaru L, Ryan J, Arnold ME. 2012. A sensitive and accurate liquid chromatography- tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclatasvir) in human plasma and urine. J Chromatogr A 1245:117-121. http://dx.doi.org/10.1016/j.chroma.2012.05.028.
    • (2012) J Chromatogr A , vol.1245 , pp. 117-121
    • Jiang, H.1    Zeng, J.2    Kandoussi, H.3    Liu, Y.4    Wang, X.5    Bifano, M.6    Cojocaru, L.7    Ryan, J.8    Arnold, M.E.9
  • 29
    • 0025958371 scopus 로고
    • Sample size determination for bioequivalence assessment by means of confidence intervals
    • Diletti E, Hauschke D, Steinijans VW. 1991. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29:1-8.
    • (1991) Int J Clin Pharmacol Ther Toxicol , vol.29 , pp. 1-8
    • Diletti, E.1    Hauschke, D.2    Steinijans, V.W.3
  • 30
    • 84924293707 scopus 로고    scopus 로고
    • Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate
    • Bifano M, Sevinsky H, Hwang C, Kandoussi H, Jiang H, Grasela D, Bertz R. 2014. Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate. Antivir Ther 19:511-519. http://dx.doi.org/10.3851/IMP2718.
    • (2014) Antivir Ther , vol.19 , pp. 511-519
    • Bifano, M.1    Sevinsky, H.2    Hwang, C.3    Kandoussi, H.4    Jiang, H.5    Grasela, D.6    Bertz, R.7
  • 31
    • 84937759225 scopus 로고    scopus 로고
    • An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects
    • Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz R. 2015. An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Invest 35:281-289. http://dx.doi.org/10.1007/s40261-015-0279-5.
    • (2015) Clin Drug Invest , vol.35 , pp. 281-289
    • Bifano, M.1    Adamczyk, R.2    Hwang, C.3    Kandoussi, H.4    Marion, A.5    Bertz, R.6
  • 32
    • 84891829801 scopus 로고    scopus 로고
    • Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: Ritonavir-boosted atazanavir, efavirenz and tenofovir
    • Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R, Velinova-Donga M, Kandoussi H, Sevinsky H, Bertz R. 2013. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 18:931-940. http://dx.doi.org/10.3851/IMP2674.
    • (2013) Antivir Ther , vol.18 , pp. 931-940
    • Bifano, M.1    Hwang, C.2    Oosterhuis, B.3    Hartstra, J.4    Grasela, D.5    Tiessen, R.6    Velinova-Donga, M.7    Kandoussi, H.8    Sevinsky, H.9    Bertz, R.10
  • 36
    • 0028833349 scopus 로고
    • Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling
    • Ohtani M, Kotaki H, Sawada Y, Iga T. 1995. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 272:505-510.
    • (1995) J Pharmacol Exp Ther , vol.272 , pp. 505-510
    • Ohtani, M.1    Kotaki, H.2    Sawada, Y.3    Iga, T.4
  • 37
    • 0030911470 scopus 로고    scopus 로고
    • Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine
    • Ohtani M, Kotaki H, Nishitateno K, Sawada Y, Iga T. 1997. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 281:428-433.
    • (1997) J Pharmacol Exp Ther , vol.281 , pp. 428-433
    • Ohtani, M.1    Kotaki, H.2    Nishitateno, K.3    Sawada, Y.4    Iga, T.5
  • 38
    • 67651208452 scopus 로고    scopus 로고
    • Buprenorphine: The basic pharmacology revisited
    • Cowan A. 2007. Buprenorphine: the basic pharmacology revisited. J Addict Med 1:68-72. http://dx.doi.org/10.1097/ADM.0b013e31806c9202.
    • (2007) J Addict Med , vol.1 , pp. 68-72
    • Cowan, A.1
  • 39
    • 0035028389 scopus 로고    scopus 로고
    • Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist
    • Huang P, Kehner GB, Cowan A, Liu-Chen LY. 2001. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297:688-695.
    • (2001) J Pharmacol Exp Ther , vol.297 , pp. 688-695
    • Huang, P.1    Kehner, G.B.2    Cowan, A.3    Liu-Chen, L.Y.4
  • 41
    • 84890099630 scopus 로고    scopus 로고
    • Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioiddependent individuals
    • Masson CL, Rainey PM, Moody DE, McCance-Katz EF. 2014. Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioiddependent individuals. Am J Addict 23:34-40. http://dx.doi.org/10.1111/j.1521-0391.2013.12052.x.
    • (2014) Am J Addict , vol.23 , pp. 34-40
    • Masson, C.L.1    Rainey, P.M.2    Moody, D.E.3    McCance-Katz, E.F.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.